Any thoughts??
Ranger43a3 days ago
MRNS and SAGE thoughts—
Hello, everyone. I’m a science guy, so let me get right to the crux of the big issue with Ganaxolone. Will this drug be as effective as SAGE’s? Depends. For pediatric disease and epilepsy, YES. For MDD and PPD, it’s a big unknown. That’s because Ganaxolone is a modified version of Allopregnanolone (SAGE’s drug), but it’s a BIG modification. Unlike SAGE’s drug, it has no effect on the Progesterone receptor. Why is this important? Because it may very well be that this MOA is why SAGE’s drug works for MDD and PPD, and Ganaxolone MAY NOT. Conversely, the negative of SAGE’s drug is that there MAY be long term steroid (Prednisone-like) side effects due to this activity on the Progesterone receptor. This IS the receptor that Prednisone binds to that causes the steroid “euphoria” and the long-term side effects. So it’s entirely possible that SAGE’s results are nothing more than a well-known steroid-like euphoria and will eventually cause long term steroid like side effects and damage. So, in summary, Marinus’s drug, Ganaxolone, may not even work for MDD or PDD, and SAGE’s drug will work early on for MDD but cannot be used long term due to steroid-like side effects. Very interesting story. Both MAY be a bust for MDD, for different reasons. But Ganaxolone will be golden for the pediatric indications.
Recent MRNS News
- Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 • Business Wire • 09/12/2024 12:00:00 PM
- Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 12:00:00 PM
- Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 • Business Wire • 08/19/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:09:04 AM
- Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results • Business Wire • 08/13/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:06 PM
- Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS • PR Newswire (US) • 08/05/2024 09:45:00 AM
- Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024 • Business Wire • 07/30/2024 12:00:00 PM
- The Gross Law Firm Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS • PR Newswire (US) • 07/25/2024 09:45:00 AM
- Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder • Business Wire • 07/18/2024 11:00:00 AM
- Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS • PR Newswire (US) • 07/17/2024 09:45:00 AM
- Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact The Gross Law Firm about pending Class Action - MRNS • PR Newswire (US) • 07/12/2024 09:45:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/08/2024 08:32:41 PM
- The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 11:01:43 AM
- Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus • Business Wire • 06/17/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/06/2024 08:55:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 10:35:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 11:05:13 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM